EUVIMEDEUVIMED entdecken
Crossref

Aβ-Targeted Theranostic Agent for NIR Fluorescence Imaging Guided Type-I and Type-II Dual Photodynamic Therapy of Alzheimer’s Disease

Guangzhao Liu, Xilei Xie, Yaxin Niu, Yong Li, Jian Zhang, Xiaoyun Jiao, Xueyu Dou, Yue Tang, Xu Wang, Bo Tang iD

Analytical Chemistry · 24.02.2026 · 98 (7) · 5677-5690

DOI: 10.1021/acs.analchem.5c07740 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical Chemistry, online erschienen am 13.02.2026. Verfasst von Guangzhao Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry, Chemical Engineering and Materials Science, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Collaborative I…. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Photochemotherapy, Optical Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Joint Program on Health Science & Technology Innovation of Hainan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the pathological aggregation of β-amyloid (Aβ), a key contributor to its pathogenesis. Current diagnostic and therapeutic strategies are hindered by limitations such as low sensitivity, high costs, limited efficacy, and severe side effects. In this study, we rationally designed a series of novel theranostic agents integrating Aβ-targeted fluorescence imaging and photodynamic therapy (PDT). Following theoretical calculations and experimental validation, we identified TA-2 as a promising candidate with superior binding affinity, excellent specificity, and a significant NIR fluorescence response to Aβ conformers. Upon NIR light activation, TA-2 generated both O2•- and 1O2 via Type I and II dual mechanisms. This dual ROS generation profile is particularly beneficial for addressing the hypoxic conditions often encountered in Alzheimer's disease (AD) pathology. The photoinduced ROS specifically oxidized critical Aβ residues, disrupting Aβ aggregation and disassembling preformed Aβ fibrils. In vitro, TA-2 demonstrated neuroprotection against Aβ-induced cytotoxicity by alleviating neuronal apoptosis. Following systemic administration, TA-2 easily crossed the blood-brain barrier, bound specifically to Aβ plaques, and enabled real-time monitoring of AD progression and therapeutic efficacy via NIR fluorescence imaging. Meanwhile, PDT with TA-2 resulted in a reduction of cerebral Aβ burden, leading to improved cognitive function in AD mice. These findings position TA-2 as a promising Aβ-targeted theranostic agent, combining both fluorescence imaging and spatiotemporally controlled PDT for AD diagnosis and treatment. This work demonstrates a new paradigm of NIR fluorescence imaging guided PDT for precise AD intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesPhotochemotherapyOptical ImagingTheranostic NanomedicinePhotosensitizing AgentsAnimalsHumansMiceInfrared RaysReactive Oxygen SpeciesFluorescent Chemosensor Compounds

Substanzen

Amyloid beta-PeptidesPhotosensitizing AgentsReactive Oxygen SpeciesFluorescent Chemosensor Compounds

Autor:innen und Institutionen

  • College of Chemistry, Chemical Engineering and Materials Science, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Univ…
  • Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan 250014, P. R. China.
  • Laoshan Laboratory, Qingdao 266237, P. R. China.

ORCID-Profile: Bo Tang

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province
  • Joint Program on Health Science & Technology Innovation of Hainan Province
  • the Project of Shandong Provincial Center for Fundamental Science Research

Zitieren

APA

Liu, G., Xie, X., Niu, Y., Li, Y., Zhang, J., Jiao, X., Dou, X., Tang, Y., Wang, X., & Tang, B. (2026). Aβ-Targeted Theranostic Agent for NIR Fluorescence Imaging Guided Type-I and Type-II Dual Photodynamic Therapy of Alzheimer’s Disease. Analytical Chemistry, 98(7), 5677-5690. https://doi.org/10.1021/acs.analchem.5c07740

Vancouver

Liu G, Xie X, Niu Y, Li Y, Zhang J, Jiao X, et al. Aβ-Targeted Theranostic Agent for NIR Fluorescence Imaging Guided Type-I and Type-II Dual Photodynamic Therapy of Alzheimer’s Disease. Analytical Chemistry. 2026;98(7):5677-5690. doi:10.1021/acs.analchem.5c07740

BibTeX
@article{Liu2026,
  author = {Liu, Guangzhao and Xie, Xilei and Niu, Yaxin and Li, Yong and Zhang, Jian and Jiao, Xiaoyun and Dou, Xueyu and Tang, Yue and Wang, Xu and Tang, Bo},
  title = {Aβ-Targeted Theranostic Agent for NIR Fluorescence Imaging Guided Type-I and Type-II Dual Photodynamic Therapy of Alzheimer’s Disease},
  journal = {Analytical Chemistry},
  year = {2026},
  volume = {98},
  number = {7},
  pages = {5677--5690},
  doi = {10.1021/acs.analchem.5c07740}
}
Kostenlos starten →